MB-dNPM1-TCR.1

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameMB-dNPM1-TCR.1

Drug Alias NameMB-CART2019.1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionNucleophosmin inhibitors

TargetsNucleophosmin

Therapy Area/IndicationsMultiple SclerosisLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsGermany

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMiltenyi Biotec

China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi Biotec Miltenyi Biomedicine Gmbh

Inactive CompaniesN/A

Active IndicationsMultiple SclerosisLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A